CJC-1295 and Ipamorelin, often studied in combination, represent a newer generation of GH-secretagogue compounds, characterized by extended half-life and receptor selectivity compared to earlier-generation peptides
doi:10.1002/jbm.b.30246
However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
How quickly does BPC 157 work
BPC 157 is often compared with other peptides like TB-500 in preclinical studies
Adequate hydration is the first-line response